1. Home
  2. MORF

MORF

Morphic Holding Inc.

Logo Morphic Holding Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.

Founded: 2014 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 1.4B IPO Year: 2019
Target Price: $61.71 AVG Volume (30 days): 495.4K
Analyst Decision: Buy Number of Analysts: 8
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.59 EPS Growth: N/A
52 Week Low/High: $19.35 - $63.08 Next Earning Date: 04-30-2024
Revenue: $521,000 Revenue Growth: -99.26%
Revenue Growth (this year): -51.06% Revenue Growth (next year): 33.33%

Share on Social Networks:

Stock Insider Trading Activity of Morphic Holding Inc. (MORF)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
SCHEGERIN MARC MORF CFO and COO Jan 12 '24 Sell $27.49 6,041 $166,071.32 37,460 SEC Form 4
Rogers Bruce MORF President Jan 12 '24 Sell $27.49 6,314 $173,576.28 142,036 SEC Form 4
Edwards Martin MORF Director Nov 13 '23 Buy $20.54 2,376 $48,803.04 2,376 SEC Form 4
SLATTERY JOSEPH P MORF Director Nov 13 '23 Buy $20.60 2,400 $49,435.68 9,066 SEC Form 4